Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine

In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for blood components promise to reduce the residual risk of known and emerging infectious agents. The implementation of PI of labile blood components is slowly but steadily increasing. This review discusse...

Descripción completa

Detalles Bibliográficos
Autor principal: Seltsam, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722787/
https://www.ncbi.nlm.nih.gov/pubmed/29255710
http://dx.doi.org/10.3389/fmed.2017.00219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722787/
https://www.ncbi.nlm.nih.gov/pubmed/29255710
http://dx.doi.org/10.3389/fmed.2017.00219

Ejemplares similares